Canada Pension Plan Investment Board Purchases Shares of 41,800 Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Canada Pension Plan Investment Board acquired a new stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 41,800 shares of the company's stock, valued at approximately $1,728,000. Canada Pension Plan Investment Board owned 0.09% of Mirum Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in the business. Geode Capital Management LLC increased its position in shares of Mirum Pharmaceuticals by 0.8% in the fourth quarter. Geode Capital Management LLC now owns 943,344 shares of the company's stock worth $39,016,000 after purchasing an additional 7,147 shares during the last quarter. Clearbridge Investments LLC grew its position in Mirum Pharmaceuticals by 2.0% in the fourth quarter. Clearbridge Investments LLC now owns 907,317 shares of the company's stock worth $37,518,000 after acquiring an additional 18,217 shares in the last quarter. Lord Abbett & CO. LLC bought a new position in Mirum Pharmaceuticals in the third quarter valued at $28,913,000. Loomis Sayles & Co. L P raised its position in Mirum Pharmaceuticals by 15.8% during the fourth quarter. Loomis Sayles & Co. L P now owns 578,024 shares of the company's stock valued at $23,901,000 after purchasing an additional 78,708 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in Mirum Pharmaceuticals by 1.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 332,639 shares of the company's stock worth $13,755,000 after purchasing an additional 4,478 shares during the last quarter.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on MIRM. Robert W. Baird boosted their target price on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an "outperform" rating in a research report on Thursday, February 27th. HC Wainwright lifted their target price on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. Ten analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $58.20.

Mirum Pharmaceuticals Trading Up 1.0 %

NASDAQ:MIRM traded up $0.42 during trading hours on Tuesday, hitting $41.73. The company had a trading volume of 47,534 shares, compared to its average volume of 519,799. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. Mirum Pharmaceuticals, Inc. has a 52 week low of $23.83 and a 52 week high of $54.23. The company has a market capitalization of $2.06 billion, a PE ratio of -20.59 and a beta of 1.00. The stock has a 50-day moving average price of $43.90 and a 200 day moving average price of $44.06.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The firm had revenue of $99.41 million during the quarter, compared to the consensus estimate of $96.64 million. On average, equities research analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Insiders Place Their Bets

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 27,279 shares of the firm's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $44.21, for a total transaction of $1,206,004.59. Following the completion of the sale, the chief executive officer now directly owns 138,641 shares in the company, valued at approximately $6,129,318.61. This trade represents a 16.44 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Peter Radovich sold 7,879 shares of the company's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $44.21, for a total transaction of $348,330.59. Following the completion of the transaction, the chief operating officer now owns 18,672 shares in the company, valued at approximately $825,489.12. This represents a 29.67 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 105,557 shares of company stock valued at $4,726,040. 22.87% of the stock is currently owned by corporate insiders.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.